发明名称 Paclitaxel enhancer compounds
摘要 Disclosed is a compound represented by the Structural Formula (I): Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R5-R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R7 and R8 are each independently —H, an aliphatic or substituted aliphatic group, or R7 is —H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is ═O or ═S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with Paclitaxel or an analog of Paclitaxel.
申请公布号 US7671092(B2) 申请公布日期 2010.03.02
申请号 US20080009641 申请日期 2008.01.18
申请人 SYNTA PHARMACEUTICALS CORP. 发明人 KOYA KEIZO;SUN LIJUN;CHEN SHOUJUN;TATSUTA NORIAKI;WU YAMING;ONO MITSUNORI
分类号 A61K31/16;A61K;A61K31/165;A61K31/175;A61K31/275;A61K31/337;A61K31/34;A61K31/341;A61K31/381;A61K31/404;A61K31/42;A61K31/4406;A61K31/5377;A61K31/661;A61P;A61P35/00;A61P43/00;C07C;C07C327/56;C07D209/42;C07D209/44;C07D213/82;C07D213/83;C07D261/18;C07D285/00;C07D305/14;C07D307/68;C07D333/38;C07D333/68;C07D333/70;C07D407/12;C07D417/00 主分类号 A61K31/16
代理机构 代理人
主权项
地址